GeneDx Holdings Corp. (WGS) intrinsic value & 10-year financials
GeneDx Holdings Corp. (WGS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 13.9% a year to $427.5M, with an average return on invested capital of -785.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $63.61
- Market cap
- $1.8B
- Revenue (FY2025)
- $427.5M
- Revenue growth (8-yr CAGR)
- 13.9%
- ROIC (10-yr avg)
- -785.5%
- Free cash flow (FY2025)
- $14.3M
WGS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $427.5M | -$21.0M | -$0.73 | $14.3M | -3.1% | -4.4% |
| FY2024 | $305.4M | -$52.3M | -$1.94 | -$34.0M | -7.6% | -8.9% |
| FY2023 | $202.6M | -$175.8M | -$7.23 | -$185.4M | -89.2% | -80.7% |
| FY2022 | $234.7M | -$549.0M | -$1.63 | -$326.3M | -284.5% | -615.0% |
| FY2021 | $212.2M | -$245.4M | -$0.76 | -$199.8M | -210.3% | -3849.4% |
| FY2020 | $179.3M | -$241.3M | -$0.74 | -$117.2M | -134.9% | -981.9% |
| FY2019 | $196.2M | -$29.7M | -$0.10 | -$30.7M | -15.5% | 42.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GeneDx Holdings Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GeneDx Holdings Corp. has historically struggled to out-earn its cost of capital, averaging just -15.2% ROIC.
GeneDx Holdings Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GeneDx Holdings Corp. is modeled at 13.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-22.81 per share.